Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
No open-market purchases or sales by Cadrenal Therapeutics, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Cadrenal Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 3 | 9 | +6 |
| Shares | 284 | 1.11M | +1.11M (+389,373.9%) |
| Value | $429 | $751.9K | +$751.5K (+175,176.7%) |
New holders (6)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 982,285 | $668.1K | 0.02% |
| Geode Capital Management, LLC | 38,745 | $26.4K | 0.00% |
| Citadel Advisors LLC | 29,114 | $19.8K | 0.00% |
| Virtu Financial LLC | 25,472 | $17.0K | 0.00% |
| Biltmore Family Office, LLC | 11,000 | $7.48K | 0.00% |
| Two Sigma Securities, LLC | 10,830 | $7.37K | 0.00% |
Sold out (0)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
None.